A deep ATCA 20cm radio survey of the AKARI Deep Field South near the South Ecliptic Pole

The results of a deep 20 cm radio survey at 20 cm are reported of the AKARI Deep Field South (ADF-S) near the South Ecliptic Pole (SEP), using the Australia Telescope Compact Array telescope, ATCA. The survey has 1 sigma detection limits ranging from 18.7--50 microJy per beam over an area of ~1.1 sq degrees, and ~2.5 sq degrees to lower sensitivity. The observations, data reduction and source count analysis are presented, along with a description of the overall scientific objectives, and a catalogue containing 530 radio sources detected with a resolution of 6.2" x 4.9". The derived differential source counts show a pronounced excess of sources fainter than ~1 mJy, consistent with an emerging population of star forming galaxies. Cross-correlating the radio with AKARI sources and archival data we find 95 cross matches, with most galaxies having optical R-magnitudes in the range 18-24 mag, and 52 components lying within 1" of a radio position in at least one further catalogue (either IR or optical). We have reported redshifts for a sub-sample of our catalogue finding that they vary between galaxies in the local universe to those having redshifts of up to 0.825. Associating the radio sources with the Spitzer catalogue at 24 microns, we find 173 matches within one Spitzer pixel, of which a small sample of the identifications are clearly radio loud compared to the bulk of the galaxies. The radio luminosity plot and a colour-colour analysis suggest that the majority of the radio sources are in fact luminous star forming galaxies, rather than radio-loud AGN. There are additionally five cross matches between ASTE or BLAST submillimetre galaxies and radio sources from this survey, two of which are also detected at 90 microns, and 41 cross-matches with submillimetre sources detected in the Herschel HerMES survey Public Data release.Comment: MNRAS accepted and in press 9 July 2012: 28 pages, 15 Figures, 17 Table

Ulam type stability problems for alternative homomorphisms

We introduce an alternative homomorphism with respect to binary operations and investigate the Ulam type stability problem for such a mapping. The obtained results apply to Ulam type stability problems for several important functional equations.ArticleJOURNAL OF INEQUALITIES AND APPLICATIONS. 2014:228 (2014)journal articl

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation